Answers are grounded in this paper and cite their sources.
Purpose. About one in five patients with colorectal cancer presents with metastatic disease, and many receive no recorded anticancer treatment. We described treatment patterns and examined survival differences by race/ethnicity, county income and rurality among adults with Stage IV colorectal cancer. Methods. Retrospective cohort of adults aged 20 years or older diagnosed in 2018-2023 in the Surveillance, Epidemiology, and End Results (SEER) program (n = 44,507 analyzed). Treatment was grouped as surgery plus chemotherapy, chemotherapy without surgery, surgery without chemotherapy, radiation only, or no recorded treatment. We used logistic regression, Kaplan-Meier methods and sequentially adjusted Cox models (3-month landmark analysis for treatment). Results. Overall, 24.8% had no recorded treatment (crude median survival 1 month). Age 75 or older versus under 50 carried the highest odds of no recorded treatment (odds ratio 7.26, 95% CI 6.56-8.03); odds were also higher for Black patients (1.31, 1.22-1.41). Three-year survival was 18.6% for Black versus 23.1% for White patients. Adjustment for treatment group attenuated the Black-White hazard ratio from 1.18 to 1.13; income and rurality estimates were unchanged. The Black-White difference was largest under age 50 (hazard ratio 1.45, 1.31-1.60) and absent at 75 and older (1.01, 0.95-1.08). Conclusions. About one in four adults with Stage IV colorectal cancer had no recorded treatment, mostly older patients. Survival differences by race/ethnicity, county income and rurality persisted after adjustment, with only slight attenuation of the Black-White difference after adjustment for recorded treatment.
No takes yet. Share an insight, caveat, or question.
Olakunle Daniel Olorunkemi (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: